Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 4/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.30 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | PRF1 | P14222 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2111414 | 1.00 | CYP3A4 (0.41) | CYP3A4SNCAF10NFE2L2BRD4 | |
| SCHEMBL2111449 | 0.87 | CYP3A4 (0.41) | CYP3A4SNCAJAK2JAK1TYK2 | |
| SCHEMBL2111450 | 0.87 | CYP3A4 (0.41) | CYP3A4SNCAJAK2JAK1TYK2 | |
| SCHEMBL2512149 | 0.75 | CYP3A4 (0.44) | CYP3A4BRD4CREBBP | |
| SCHEMBL2745819 | 0.75 | CYP3A4 (0.43) | CYP3A4SNCABRD4CREBBPPIP4K2A | |
| SCHEMBL2512148 | 0.75 | CYP3A4 (0.44) | CYP3A4BRD4CREBBP | |
| SCHEMBL2745821 | 0.75 | CYP3A4 (0.43) | CYP3A4SNCABRD4CREBBPPIP4K2A | |
| SCHEMBL2112174 | 0.74 | CYP3A4 (0.59) | CYP3A4SNCAF10 | |
| SCHEMBL2112172 | 0.74 | CYP3A4 (0.59) | CYP3A4SNCAF10 | |
| SCHEMBL2111628 | 0.73 | CYP3A4 (0.41) | CYP3A4F10BRD4PIP4K2APIP4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158631-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330032-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RTF2 | CYP3A4 305/4885SNCA 3590/4885F10 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.